Novel, tumor-selective therapies are needed to increase the survival rate of pancreatic cancer patients. K-Ras-mutant-driven NAD(P)H:quinone oxidoreductase 1 (NQO1) is over-expressed in pancreatic tumor versus associated normal tissue, while catalase expression is lowered wileyonlinelibrary.com/journal/jso
| INTRODUCTION
Pancreatic cancer has risen in incidence and is a historically recalcitrant disease that is expected to be the second leading cause of cancerrelated deaths by 2020. 1, 2 Current therapies against pancreatic cancer lack rationale that exploit cancer-specific targets, are subject to inherent resistance mechanisms and are ineffective against noncycling cancer cells. Effective treatment for pancreatic cancer will require use of agents that cause tumor-specific cell death, independent of oncogenic driver mutations such as Kras and p53, or apoptotic processes (eg, caspase-independent). A majority of cancers lack functional p53, have activated or mutant tumor driver mutations, and/ or have defects in apoptotic pathways that confer growth advantages and drug resistance. 3, 4 Agents that kill pancreatic cancer cells irrespective of growth state (ie, effective against stationary and logphase cells) and target primary and metastatic tumor cells are needed, since resistant, growth-arrested cancer (stem-like) cells can repopulate a tumor or metastasize.
NAD(P)H:quinone oxidoreductase 1 (NQO1) expression is an exploitable, tumor-specific target for pancreatic cancer therapies.
Elevated NQO1 expression is noted in many early forms of cancers such as in pancreatic intraepithelial neoplasia (PanINs), 5 prostatic intraepithelial neoplasia, 6, 7 and breast ductal carcinoma in situ 8, 9 and further increase in this enzyme occurs as these cancers progress. levels, believed mainly due to mutant K-Ras driven transcription. 5, 16 We assessed NQO1 mRNA levels in 462 pancreatic adenocarcinoma tissues versus associated normal tissue, where uniformly elevated NQO1 levels were noted, consistent with our prior data. 17 As also A, NQO1-mediated cell death by ß-lap. Note the combined futile cycle mechanism of NQO1-mediated redox cycling and H 2 O 2 -induced PARP1 hyperactivation reduce NAD(P)H equivalents that stimulates NAD + elimination by GAPD-SNO-NAD conjugation (glycolysis inhibition) and PARP1 ADP-ribosylation hyperactivation and cell death at sublethal doses of both the DNA damaging agent(s) and β-lapachone. 6, 11, 16, 29 We are leading the clinical development of a novel NQO1 bioactivatable drug, β-lapachone (used as HPßCD-ß-lap, ARQ761). ) follow the doses used in the MPACT clinical trial. 31 The maximum tolerated dose (MTD) of ARQ761 will be determined by dosetitrating using a standard 3 + 3 method, as highlighted in Table 1. 36 Three patients within a dose level will be observed for one cycle (28 days) before accrual to the next higher dose level may begin. If a subject is withdrawn from the study prior to completing 22 days of combination therapy without experiencing a Dose limiting toxicity (DLT) prior to withdrawal, an additional subject may be added to that dose level. If a subject misses two doses for reasons other than adverse events, an additional subject may be added to that dose level. For the dose expansion phase of the study, there will be no replacements of subjects made. 
| TUMOR RESPONSE AND TOXICITY MONITORING
Disease response and progression will be evaluated in this study using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee. 32 Any patient who receives treatment on this protocol will be evaluable for toxicity. Toxicity will be assessed according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE), version 4.0. The most common adverse events noted with the MPACT study that resulted in a dose reduction, delay or withholding of chemotherapy was neutropenia and thrombocytopenia. 31 We will follow standard recommended dose modifications for gemcitabine and nab-paclitaxel per the MPACT trial.
| PHARMACOKINETIC AND PHARMACODYNAMIC SAMPLING
Serial venous blood samples will be drawn from each subject during the first cycle on days 1 and 15 for determination of plasma levels of ARQ761. Serial venous blood samples will be drawn from each subject before and 3 h after cycle 1 days 1 and 15 infusions of study drug for biomarker analyses.
Tumor biopsies will be performed at baseline (if not available) and after cycle 1. The goal of the planned laboratory correlative studies is discussed in the exploratory objectives indicated above. The purpose of the follow up biopsy is to inform the mechanism of action of ARQ761 and chemotherapy and will drive the translational aspect of the study. The planned analysis includes immunohistochemistry (IHC)
analysis of NQO1, catalase, TUNEL, Ki-67, and ϒ-H2AX by IHC.
Additional analysis by western blot for μ-calpain and PARP cleavage will be performed.
| CONCLUSION
Rational hypothesis driven treatments for pancreatic cancer that exploit a well-defined mechanism of action are needed. Difficulty in obtaining pancreatic cancer tumor tissue has hampered the ability to develop markers of response and predictors of efficacy in this field.
This phase 1 clinical trial explores a novel bioactivatable compound, ARQ761 to target pancreatic cancer therapy and pharmacodynamic markers will validate NQO1: catalase expression as a predictive biomarker of response.
